Dogwood Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses (Tables)

6 Months Ended

Jun. 30, 2023


	June 30,		December 31,
	2023		2022
Accrued interest on preferred members’ interests	$	188,085	$	188,085
Accrued compensation		62,735		159,704
Accrued professional fees		41,950		11,600
Accrued clinical research costs		7,807		78,349
Accrued director fees		—		31,000
Other miscellaneous accrued expenses		5,150		1,360
	$	305,727	$	470,098